Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Longboard Pharmaceuticals Inc (NQ: LBPH ) 37.27 +2.48 (+7.13%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Longboard Pharmaceuticals Inc < Previous 1 2 3 4 Next > Apple, Longboard Pharmaceuticals, Coinbase, Moderna, Tesla: Why These 5 Stocks Are On Investors' Radars Today January 02, 2024 U.S. stocks experienced mixed results in Tuesday’s trading session. The Dow Jones index showed resilience, gaining around 25 points, a modest rise of 0.07% to 37,715.04. In contrast, the tech-heavy... Via Benzinga Topics Stocks Exposures US Equities Why Longboard Pharma Catapulted 316%, Leading A Biotech Stock Rally January 02, 2024 Longboard Pharmaceuticals is working on treatments for seizure disorders. Via Investor's Business Daily Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock January 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Crude Oil Down 2%; Tesla Deliveries Top Estimates January 02, 2024 U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded up 0.01% to 37,691.77 while the NASDAQ fell 1.78% to... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities The Latest Analyst Ratings for Longboard Pharmaceuticals October 24, 2023 Via Benzinga The Latest Analyst Ratings for Longboard Pharmaceuticals June 27, 2023 Via Benzinga The Latest Analyst Ratings for Longboard Pharmaceuticals May 10, 2023 Via Benzinga There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target January 02, 2024 Tuesday, Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of... Via Benzinga Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session January 02, 2024 Shares of Longboard Pharmaceuticals, Inc. Via Benzinga Why Is Longboard Pharmaceuticals (LBPH) Stock Up 175% Today? January 02, 2024 With Longboard Pharmaceuticals delivering positive clinical trial data, LBPH stock soared on the positive therapeutic implications. Via InvestorPlace 12 Health Care Stocks Moving In Tuesday's Intraday Session January 02, 2024 Via Benzinga Dow Turns Higher; Anavex Life Sciences Shares Plunge January 02, 2024 U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Tuesday. The Dow traded up 0.13% to 37,739.18 while the NASDAQ fell 1.29% to 14,818.23. The S&P 500... Via Benzinga Topics Stocks Exposures US Equities Neurology-Focused Longboard Pharmaceuticals' Stock Soars Over 200% Today - Here's Why January 02, 2024 Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental Via Benzinga Dow Down 100 Points; US Manufacturing PMI Falls In December January 02, 2024 U.S. stocks traded lower this morning, with the Dow Jones index falling more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.28% to 37,584.41 while the NASDAQ... Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Tuesday's Pre-Market Session January 02, 2024 Via Benzinga Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs) January 02, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs) January 01, 2024 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers November 29, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community November 21, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) November 03, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results November 02, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November November 01, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023 October 05, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023 September 19, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences August 31, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings August 30, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies August 23, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results August 03, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Present at Upcoming Investor Conferences August 03, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire Longboard Pharmaceuticals to Participate in Fireside Chat with Cantor on Friday, June 30, 2023 June 26, 2023 From Longboard Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.